Thursday, March 26, 2020 11:22:00 PM
Interesting analysis. Here is mine:
Support at 7.91, 7.75
Resistance at 8.09, 8.35, 8.90 (also currently 200 dma)
MACD lagging indicator - positive crossover on daily at close
Stoch is a leading indicator - turned up on March 18 for daily with decent potential upside
RSI of no consequence - 50 on 30 min and 40 on daily
On 30 minute:
Stoch turned up at 3pm today potential for good day tomorrow
Support tends to follow the 50 ma
Resistance tends to follow the 200 ma
Potential for a golden cross tomorrow or Monday - meaning
Potential for a short term pinch
Weekly Stoch still negative, but converging quickly.
There is a potential breakout over the next couple of days. May have a second try at breaking through 8.35. Looking to test 8.90 very soon. Keep an eye on the daily and weekly Stoch.
Tuesday is March 31. Teva announced that they will have 6 mil hydrochloroquine and chloroquine tablets to hospitals by Tuesday. A PR would be expected. This could be a catalyst to push it over 8.90. Otherwise, expect heavy resistance in that range.
Support at 7.91, 7.75
Resistance at 8.09, 8.35, 8.90 (also currently 200 dma)
MACD lagging indicator - positive crossover on daily at close
Stoch is a leading indicator - turned up on March 18 for daily with decent potential upside
RSI of no consequence - 50 on 30 min and 40 on daily
On 30 minute:
Stoch turned up at 3pm today potential for good day tomorrow
Support tends to follow the 50 ma
Resistance tends to follow the 200 ma
Potential for a golden cross tomorrow or Monday - meaning
Potential for a short term pinch
Weekly Stoch still negative, but converging quickly.
There is a potential breakout over the next couple of days. May have a second try at breaking through 8.35. Looking to test 8.90 very soon. Keep an eye on the daily and weekly Stoch.
Tuesday is March 31. Teva announced that they will have 6 mil hydrochloroquine and chloroquine tablets to hospitals by Tuesday. A PR would be expected. This could be a catalyst to push it over 8.90. Otherwise, expect heavy resistance in that range.
Recent TEVA News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • Business Wire • 02/20/2026 08:37:00 PM
- Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI • Business Wire • 02/20/2026 08:37:00 PM
- U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 02/20/2026 07:43:11 PM
- Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease • GlobeNewswire Inc. • 02/17/2026 11:00:00 AM
- Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatrique • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/03/2026 01:58:40 PM
- Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential • GlobeNewswire Inc. • 01/28/2026 12:00:00 PM
